Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zimmer Biomet Holdings (ZBH) and Amphastar Pharmaceuticals (AMPH).
Zimmer Biomet Holdings (ZBH)
In a report released today, Jason Wittes from Northland Securities maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $150.00. The company’s shares closed last Friday at $138.52.
According to TipRanks.com, Wittes is a 4-star analyst with an average return of 11.6% and a 58.8% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Globus Medical, and Stereotaxis.
Currently, the analyst consensus on Zimmer Biomet Holdings is a Strong Buy with an average price target of $159.92, implying a 14.4% upside from current levels. In a report issued on October 27, Cowen & Co. also maintained a Hold rating on the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
Amphastar Pharmaceuticals (AMPH)
In a report released today, Tim Chiang from Northland Securities maintained a Buy rating on Amphastar Pharmaceuticals, with a price target of $24.00. The company’s shares closed last Friday at $19.20.
According to TipRanks.com, Chiang is a 1-star analyst with an average return of -1.7% and a 44.8% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Pacira Pharmaceuticals, and Kala Pharmaceuticals.
Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
